98%
921
2 minutes
20
In contrast to red blood cells, platelets float rather than sediment when a column of blood is placed in the gravitational field. By the analogy of erythrocyte sedimentation (ESR), it can be expressed with the platelet antisedimentation rate (PAR), which quantitates the difference in platelet count between the upper and lower halves of the blood column after 1 h of 1 g sedimentation. Venous blood samples from 21 healthy subjects were analyzed for PAR. After a 1-h sedimentation, the upper and lower fractions of blood samples were analyzed for platelet count, mean platelet volume (MPV), immature platelet fraction (IPF), and high-fluorescence IPF (H-IPF). The mechanisms behind platelet flotation were explored by further partitioning of the blood column, time-dependent measurements of platelet count and comparison with ESR. The structure and function of the platelets were assessed by electron microscopy (EM) and atomic force microscopy (AFM), and platelet aggregometry, respectively. Platelet antisedimentation is driven by density differences and facilitated by a size-exclusion mechanism caused by progressive erythrocyte sedimentation. The area under the curve (AUC) of the whole blood adenosine diphosphate (ADP) aggregation curves showed significant differences between the upper and lower samples ( < .005). AUC in the upper samples of 38% of healthy subjects exceeded the top of the normal range (53-122) suggesting that ascending platelets show an intensified ADP-induced aggregability ex vivo. H-IPF was significantly higher in the upper samples ( < .05). EM and AFM revealed that platelets in the upper samples were larger in volume and contained 1.6 times more alpha granules compared to platelets in the lower samples. Our results indicate that antisedimentation is able to differentiate platelet populations based on their structural and functional properties. Therefore, PAR may be a suitable laboratory parameter in various thromboinflammatory disorders.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/09537104.2023.2298341 | DOI Listing |
Arch Cardiovasc Dis
August 2025
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, No. 2 Anzhen Road, Chaoyang District, Beijing 100029, China. Electronic address:
J Thromb Haemost
September 2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy. Electronic address:
Background: Caplacizumab, a humanized anti-von Willebrand Factor (VWF) Nanobody®, is employed for immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) treatment. Its binding to the VWF A1 domain sterically inhibits VWF interaction with platelet glycoprotein Ib (GPIb), counteracting microthrombosis and accelerating the normalization of the platelet count. In caplacizumab-treated iTTP patients with bleeding episodes, measuring platelet-dependent VWF activity (VWF activity) is crucial for monitoring treatment with VWF concentrates.
View Article and Find Full Text PDFClinics (Sao Paulo)
September 2025
School of Integrated Traditional Chinese and Western Medicine, Anhui University of Chinese Medicine, China. Electronic address:
Background: This study explores potential associations between asthma and the Systemic Immune-Inflammation Index (SII).
Methods: The study primarily focuses on adults with complete data on SII and asthma from the National Health and Nutrition Examination Survey database (2015-2020). SII is calculated using the formula: platelet count × neutrophil count / lymphocyte count.
Crit Care Explor
September 2025
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Objective: To identify distinct phenotypes of acute respiratory distress syndrome (ARDS) developing after hematopoietic cell transplantation (HCT), using routinely available clinical data at ICU admission.
Design: Multicenter retrospective cohort study using latent class analysis.
Setting: ICUs across three Mayo Clinic campuses (Minnesota, Florida, and Arizona).
JACC Case Rep
September 2025
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan.
Background: Surgical treatment for infective endocarditis (IE) with severe thrombocytopenia is considered high risk and is often avoided.
Case Summary: A 67-year-old man with a history of 3 open-heart surgeries presented with fever and severe thrombocytopenia accompanied by a bleeding tendency. Blood cultures and transthoracic echocardiography confirmed IE of the aortic bioprosthetic valve caused by Candida parapsilosis.